Mansoor R. Mirza, MD, and Robert L. Coleman, MD, on Integrating Velaparib With Chemotherapy and Maintenance Therapy in Gynecologic Cancers
ESMO 2019 Congress
Mansoor R. Mirza, MD, of Copenhagen University Hospital, and Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center, discuss phase III study findings, which showed that by adding veliparib to front-line carboplatin and paclitaxel and continuing it as monotherapy maintenance, the PARP inhibitor extended progression-free survival in women with newly diagnosed high-grade serous carcinoma of the ovaries or fallopian tubes or tumors of primary peritoneal origin (Abstract LBA3).
Related Videos
Suresh S. Ramalingam, MD, of Emory University, discusses results from the final overall survival analysis of the phase III FLAURA trial in EGFR-mutated advanced non–...
Aleix Prat, MD, PhD, of Hospital Clinic de Barcelona, discusses the findings of a meta-analysis showing that the HER2-E subtype may predict pathologic complete response beyon...
Laura Q.M. Chow, MD, of the University of Texas at Austin, Dell Medical School and LIVESTRONG Cancer Institutes, discusses phase II study findings that showe...
Sherene Loi, MD, PhD, of Peter MacCallum Cancer Centre at the University of Melbourne, and Leisha A. Emens, MD, PhD, of UPMC Hillman Cancer Center, discuss o...
Tim Meyer, PhD, of the University College London, and Lorenza Rimassa, MD, of Humanitas Research Hospital, Milan, discuss their phase III findings on prognos...
